Insider · CIK 0001817160
Gwenn Hansen
Files at NRIX (Nurix Therapeutics, Inc.). First filing Nov 1, 2023, latest Sep 1, 2026.
In brief
Gwenn Hansen files SEC Form 4 as officer at NRIX (Nurix Therapeutics, Inc.). Since Nov 1, 2023, Gwenn Hansen has reported 0 open-market buys worth $0 and 14 open-market sells worth $905k, the latest filed on Sep 1, 2026.
A track record needs three past buys with six months of prices behind them; Gwenn Hansen has 0, so none is measured yet.
The newest scored trade: sold $37k of NRIX on Sep 1, 2026, filed Sep 1, 2026, scored 0 (weak), under a 10b5-1 plan. In the last 12 months: 0 buys worth $0 and 8 sells worth $631k.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
NRIX: Nurix Therapeutics, Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 0Weak | Nurix Therapeutics, Inc. | $37k 1,452 shares | -1% | - | |
| 20Weak | Nurix Therapeutics, Inc. | $100k 4,111 shares | -3% | +200% from low0% from high | |
| 5Weak | Nurix Therapeutics, Inc. | $109k 4,356 shares | -4% | +205% from low0% from high | |
| 24Weak | Nurix Therapeutics, Inc. | $90k 3,847 shares | -3% | +186% from low-5% from high | |
| 13Weak | Nurix Therapeutics, Inc. | $108k 5,394 shares | -4% | +173% from low0% from high | |
| 22Weak | Nurix Therapeutics, Inc. | $53k 3,214 shares | -3% | +103% from low-22% from high | |
| 24Weak | Nurix Therapeutics, Inc. | $81k 4,895 shares | -6% | +100% from low-23% from high | |
| 22Weak | Nurix Therapeutics, Inc. | $52k 4,087 shares | -5% | +55% from low-55% from high | |
| 22Weak | Nurix Therapeutics, Inc. | $52k 4,308 shares | -6% | +35% from low-58% from high | |
| 21Weak | Nurix Therapeutics, Inc. | $39k 3,377 shares | -5% | +31% from low-59% from high | |
| 8Weak | NRIXsell Nurix Therapeutics, Inc. | $73k 3,690 shares | -6% | - | |
| 24Weak | Nurix Therapeutics, Inc. | $84k 3,437 shares | -6% | - | |
| 15Weak | Nurix Therapeutics, Inc. | $19k 2,334 shares | -6% | +88% from low-40% from high | |
| 15Weak | Nurix Therapeutics, Inc. | $8,487 1,633 shares | -5% | +32% from low-62% from high |
Planned sales
Form 144 notices this insider filed before selling restricted or control stock, newest first.
| Filed | Company | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| Aug 5, 2026 | NRIX NURIX THERAPEUTICS, INC. | 8,712 0.01% of outstanding | $215k | Aug 5, 2026 | $298k |
| Aug 4, 2026 | NRIX NURIX THERAPEUTICS INC | 4,111 0.00% of outstanding | $95k | Aug 4, 2026 | $108k |
| Jun 25, 2026 | NRIX NURIX THERAPEUTICS INC | 5,394 0.01% of outstanding | $104k | Jun 25, 2026 | $53k |
Transactions
The newest 50 of 92 rows this insider has filed.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Sep 1, 2026 | NRIX Nurix Therapeutics, Inc. | MOption exercise Common Stock10b5-1 | +1,452 | $1.86 | $2,701 | 118,679 | 43 d ago |
| Sep 1, 2026 | NRIX Nurix Therapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -1,452 | $25.47 | $37k | 117,227 | 43 d ago |
| Sep 1, 2026 | NRIX Nurix Therapeutics, Inc. | MOption exercise Employee Stock Option (right to buy)derivative10b5-1 | -1,452 | $0.00 | $0 | 60,858 | 43 d ago |
| Aug 5, 2026 | NRIX Nurix Therapeutics, Inc. | MOption exercise Common Stock10b5-1 | +4,356 | $1.86 | $8,102 | 121,583 | Aug 5, 2026 |
| Aug 4, 2026 | NRIX Nurix Therapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -1,500 | $23.87 | $36k | 119,838 | Aug 5, 2026 |
| Aug 4, 2026 | NRIX Nurix Therapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -2,611 | $24.64 | $64k | 117,227 | Aug 5, 2026 |
| Aug 5, 2026 | NRIX Nurix Therapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -4,356 | $25.00 | $109k | 117,227 | Aug 5, 2026 |
| Aug 5, 2026 | NRIX Nurix Therapeutics, Inc. | MOption exercise Employee Stock Option (right to buy)derivative10b5-1 | -4,356 | $0.00 | $0 | 62,310 | Aug 5, 2026 |
| Jul 30, 2026 | NRIX Nurix Therapeutics, Inc. | MOption exercise Common Stock | +3,750 | $0.00 | $0 | 118,755 | Jul 30, 2026 |
| Jul 30, 2026 | NRIX Nurix Therapeutics, Inc. | MOption exercise Common Stock | +2,858 | $0.00 | $0 | 121,613 | Jul 30, 2026 |
| Jul 30, 2026 | NRIX Nurix Therapeutics, Inc. | MOption exercise Common Stock | +3,572 | $0.00 | $0 | 125,185 | Jul 30, 2026 |
| Jul 30, 2026 | NRIX Nurix Therapeutics, Inc. | SOpen-market sale Common Stock | -3,847 | $23.38 | $90k | 121,338 | Jul 30, 2026 |
| Jul 30, 2026 | NRIX Nurix Therapeutics, Inc. | MOption exercise Restricted Stock Unitsderivative | -3,750 | $0.00 | $0 | 11,250 | Jul 30, 2026 |
| Jul 30, 2026 | NRIX Nurix Therapeutics, Inc. | MOption exercise Restricted Stock Unitsderivative | -2,858 | $0.00 | $0 | 20,009 | Jul 30, 2026 |
| Jul 30, 2026 | NRIX Nurix Therapeutics, Inc. | MOption exercise Restricted Stock Unitsderivative | -3,572 | $0.00 | $0 | 39,303 | Jul 30, 2026 |
| Jun 25, 2026 | NRIX Nurix Therapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -5,394 | $20.00 | $108k | 115,005 | Jun 25, 2026 |
| Apr 30, 2026 | NRIX Nurix Therapeutics, Inc. | MOption exercise Common Stock | +2,000 | $0.00 | $0 | 117,005 | Apr 30, 2026 |
| Apr 30, 2026 | NRIX Nurix Therapeutics, Inc. | MOption exercise Common Stock | +3,750 | $0.00 | $0 | 120,755 | Apr 30, 2026 |
| Apr 30, 2026 | NRIX Nurix Therapeutics, Inc. | MOption exercise Common Stock | +2,858 | $0.00 | $0 | 123,613 | Apr 30, 2026 |
| Apr 30, 2026 | NRIX Nurix Therapeutics, Inc. | SOpen-market sale Common Stock | -3,214 | $16.65 | $53k | 120,399 | Apr 30, 2026 |
| Apr 30, 2026 | NRIX Nurix Therapeutics, Inc. | MOption exercise Restricted Stock Unitsderivative | -2,000 | $0.00 | $0 | 0 | Apr 30, 2026 |
| Apr 30, 2026 | NRIX Nurix Therapeutics, Inc. | MOption exercise Restricted Stock Unitsderivative | -3,750 | $0.00 | $0 | 15,000 | Apr 30, 2026 |
| Apr 30, 2026 | NRIX Nurix Therapeutics, Inc. | MOption exercise Restricted Stock Unitsderivative | -2,858 | $0.00 | $0 | 22,867 | Apr 30, 2026 |
| Feb 10, 2026 | NRIX Nurix Therapeutics, Inc. | AGrant or award Employee Stock Option (right to buy)derivative | +93,750 | $0.00 | $0 | 93,750 | Feb 10, 2026 |
| Feb 10, 2026 | NRIX Nurix Therapeutics, Inc. | AGrant or award Restricted Stock Unitsderivative | +42,875 | $0.00 | $0 | 42,875 | Feb 10, 2026 |
| Feb 3, 2026 | NRIX Nurix Therapeutics, Inc. | MOption exercise Common Stock | +31,333 | $0.84 | $26k | 115,005 | Feb 3, 2026 |
| Feb 3, 2026 | NRIX Nurix Therapeutics, Inc. | MOption exercise Employee Stock Option (right to buy)derivative | -31,333 | $0.00 | $0 | 0 | Feb 3, 2026 |
| Jan 30, 2026 | NRIX Nurix Therapeutics, Inc. | MOption exercise Common Stock | +3,207 | $0.00 | $0 | 79,958 | Jan 30, 2026 |
| Jan 30, 2026 | NRIX Nurix Therapeutics, Inc. | MOption exercise Common Stock | +2,000 | $0.00 | $0 | 81,958 | Jan 30, 2026 |
| Jan 30, 2026 | NRIX Nurix Therapeutics, Inc. | MOption exercise Common Stock | +3,750 | $0.00 | $0 | 85,708 | Jan 30, 2026 |
| Jan 30, 2026 | NRIX Nurix Therapeutics, Inc. | MOption exercise Common Stock | +2,859 | $0.00 | $0 | 88,567 | Jan 30, 2026 |
| Jan 30, 2026 | NRIX Nurix Therapeutics, Inc. | SOpen-market sale Common Stock | -4,797 | $16.58 | $80k | 83,770 | Jan 30, 2026 |
| Jan 30, 2026 | NRIX Nurix Therapeutics, Inc. | SOpen-market sale Common Stock | -98 | $17.37 | $1,702 | 83,672 | Jan 30, 2026 |
| Jan 30, 2026 | NRIX Nurix Therapeutics, Inc. | MOption exercise Restricted Stock Unitsderivative | -3,207 | $0.00 | $0 | 0 | Jan 30, 2026 |
| Jan 30, 2026 | NRIX Nurix Therapeutics, Inc. | MOption exercise Restricted Stock Unitsderivative | -2,000 | $0.00 | $0 | 2,000 | Jan 30, 2026 |
| Jan 30, 2026 | NRIX Nurix Therapeutics, Inc. | MOption exercise Restricted Stock Unitsderivative | -3,750 | $0.00 | $0 | 18,750 | Jan 30, 2026 |
| Jan 30, 2026 | NRIX Nurix Therapeutics, Inc. | MOption exercise Restricted Stock Unitsderivative | -2,859 | $0.00 | $0 | 25,725 | Jan 30, 2026 |
| Oct 30, 2025 | NRIX Nurix Therapeutics, Inc. | MOption exercise Common Stock | +3,207 | $0.00 | $0 | 72,230 | Oct 30, 2025 |
| Oct 30, 2025 | NRIX Nurix Therapeutics, Inc. | MOption exercise Common Stock | +2,000 | $0.00 | $0 | 74,230 | Oct 30, 2025 |
| Oct 30, 2025 | NRIX Nurix Therapeutics, Inc. | MOption exercise Common Stock | +3,750 | $0.00 | $0 | 77,980 | Oct 30, 2025 |
| Oct 30, 2025 | NRIX Nurix Therapeutics, Inc. | MOption exercise Common Stock | +2,858 | $0.00 | $0 | 80,838 | Oct 30, 2025 |
| Oct 30, 2025 | NRIX Nurix Therapeutics, Inc. | SOpen-market sale Common Stock | -4,087 | $12.80 | $52k | 76,751 | Oct 30, 2025 |
| Oct 30, 2025 | NRIX Nurix Therapeutics, Inc. | MOption exercise Restricted Stock Unitsderivative | -3,207 | $0.00 | $0 | 3,207 | Oct 30, 2025 |
| Oct 30, 2025 | NRIX Nurix Therapeutics, Inc. | MOption exercise Restricted Stock Unitsderivative | -2,000 | $0.00 | $0 | 4,000 | Oct 30, 2025 |
| Oct 30, 2025 | NRIX Nurix Therapeutics, Inc. | MOption exercise Restricted Stock Unitsderivative | -3,750 | $0.00 | $0 | 22,500 | Oct 30, 2025 |
| Oct 30, 2025 | NRIX Nurix Therapeutics, Inc. | MOption exercise Restricted Stock Unitsderivative | -2,858 | $0.00 | $0 | 28,584 | Oct 30, 2025 |
| Oct 14, 2025 | NRIX Nurix Therapeutics, Inc. | AGrant or award Restricted Stock Unitsderivative | +20,000 | $0.00 | $0 | 20,000 | Oct 23, 2025 |
| Jul 30, 2025 | NRIX Nurix Therapeutics, Inc. | MOption exercise Common Stock | +3,207 | $0.00 | $0 | 64,723 | Jul 30, 2025 |
| Jul 30, 2025 | NRIX Nurix Therapeutics, Inc. | MOption exercise Common Stock | +2,000 | $0.00 | $0 | 66,723 | Jul 30, 2025 |
| Jul 30, 2025 | NRIX Nurix Therapeutics, Inc. | MOption exercise Common Stock | +3,750 | $0.00 | $0 | 70,473 | Jul 30, 2025 |
Questions about Gwenn Hansen
Answered from the filings on this page, as of the latest one.
Is Gwenn Hansen buying or selling?
In the last 12 months Gwenn Hansen reported 0 open-market buys worth $0 and 8 open-market sells worth $631k on SEC Form 4; the latest was sold $37k of NRIX on Sep 1, 2026. Grants, option exercises and tax withholding are not counted.
How did Gwenn Hansen's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Gwenn Hansen has 0.
Where does Gwenn Hansen file Form 4?
Gwenn Hansen has filed Form 4 at NRIX (Nurix Therapeutics, Inc.) as Chief Scientific Officer. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.